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The positron emission tomography (PET) radiotracer Pittsburgh Compound-B (PiB) binds with high affinity to
b-pleated sheet aggregates of the amyloid-b (Ab)p e p t i d ein vitro.Thein vivo retention of PiB in brains of people
with Alzheimer’s disease shows a regional distribution that is very similar to distribution of Ab deposits
observed post-mortem. However, the basis for regional variations in PiB binding in vivo,a n dt h ee x t e n tt o
which it binds to different types of Ab-containing plaques and tau-containing neurofibrillary tangles (NFT),
has not been thoroughly investigated. The present study examined 28 clinically diagnosed and autopsy-
confirmed Alzheimer’s disease subjects, including one Alzheimer’s disease subject who had undergone PiB-
PET imaging 10 months prior to death, to evaluate region- and substrate-specific binding of the highly fluores-
cent PiB derivative 6-CN-PiB.These data were then correlated with region-matched Abplaque load and peptide
levels, [
3H]PiB binding in vitro,a n din vivo PETretention levels.We found that in Alzheimer’s disease brain tissue
sections, the preponderance of 6-CN-PiB binding is in plaques immunoreactive to either Ab42 or Ab40, andto
vascular Ab deposits. 6-CN-PiB labelling was most robust in compact/cored plaques in the prefrontal and tem-
poral cortices.While diffuse plaques, including those in caudate nucleus and presubiculum, were less prominently
labelled, amorphous Ab plaques in the cerebellum were not detectable with 6-CN-PiB.Only a small subset of
NFT were 6-CN-PiB positive; these resembled extracellular ‘ghost’ NFT. In Alzheimer’s disease brain tissue
homogenates, there was a direct correlation between [
3H]PiB binding and insoluble Ab peptide levels. In the
Alzheimer’s disease subject who underwent PiB-PET prior to death, in vivo PiB retention levels correlated
directly with region-matched post-mortem measures of [
3H]PiB binding, insoluble Ab peptide levels, 6-CN-
PiB- and Ab plaque load, but not with measures of NFT. These results demonstrate, in a typical Alzheimer’s
disease brain, that PiB binding is highly selective for insoluble (fibrillar) Ab deposits, and not for neurofibrillary
pathology. The strong direct correlation of in vivo PiB retention with region-matched quantitative analyses of
Ab plaques in the same subject supports the validity of PiB-PET imaging as a method for in vivo evaluation
of Ab plaque burden.
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Introduction
Clinically symptomatic Alzheimer’s disease can be diag-
nosed with high accuracy at academic centres (Lopez et al.,
2000a, b), but diagnosis in the community is less accurate
(Pearl, 1997). Non-Alzheimer’s disease dementia cases are
not infrequently misdiagnosed as Alzheimer’s disease
(Mayeux et al., 1998), and an emerging issue is the accu-
rate prediction of conversion of patients with mild
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(Gauthier et al., 2006). For optimal treatment, it is also
critical to identify hallmark Alzheimer’s disease pathology
as early as possible. This pathology includes b-pleated sheet
protein aggregates of amyloid-b (Ab) peptides in senile
plaques (SP) and hyperphosphorylated tau protein in
neurofibrillary tangles (NFT) (Khachaturian, 1985; Mirra
et al., 1991; Consensus, 1998). The development of anti-
amyloid therapies (Nicoll et al., 2006) further emphasizes
the need for a technology to assess treatment efficacy in
individual patients. Thus sensitive in vivo markers of
Alzheimer’s disease brain lesions are needed (Consensus,
1998; Klunk, 1998; Growdon, 1999; Morris et al., 2005;
Thal et al., 2006).
Positron emission tomography (PET) imaging of amyloid
deposits (Klunk et al., 2004; Verhoeff et al., 2004; Small
et al., 2006) employs blood–brain barrier penetrant
amyloid-binding compounds such as the thioflavin-T
derivative Pittsburgh Compound-B (PiB) (Klunk et al.,
2001, 2004; Mathis et al., 2002, 2004, 2005). Compared to
age-matched, cognitively intact controls, Alzheimer’s disease
patients have 2- to 3-fold greater PiB retention on PET
scans in brain areas known to have high amounts of
fibrillar (i.e. Congo red and thioflavin-S labelled) Ab
plaques in Alzheimer’s disease, such as frontal cortex and
temporal lobe (Klunk et al., 2004; Price et al., 2005).
Conversely, brain areas relatively unaffected by fibrillar Ab
pathology, such as the cerebellum, do not have increased
PiB retention in Alzheimer’s disease subjects. In agreement
with these observations in vivo, studies of post-mortem
Alzheimer’s disease brain homogenates show that PiB binds
preferentially to Ab fibrils (Klunk et al., 2003a), suggesting
that PiB imaging could serve as a tool for monitoring
changes in Ab pathology in Alzheimer’s disease. However,
the evidence of a direct correlation between in vivo PiB-PET
retention levels and Ab plaques in the same subject is
lacking. A recent study of a subject diagnosed with
dementia with Lewy bodies, who at autopsy manifested
severe vascular Ab40 peptide-containing amyloid and infre-
quent SP, demonstrated that vascular amyloidosis can con-
tribute significantly to PiB-PET signal (Bacskai et al., 2007),
as did a study of cerebral amyloid angiopathy (CAA)
(Johnson et al., 2007), while Lewy bodies themselves
contributed little if at all to overall PiB-PET signal
(Fodero-Tavoletti et al., 2007). An in vitro study, comparing
PiB autoradiography signal with Ab/amyloid immuno/
histology in adjacent autopsy tissue sections, reported a
close correspondence of PiB signal with vascular amyloid
and Ab plaques in Alzheimer’s disease, and with NFT in
a non-Alzheimer’s disease case (Lockhart et al., 2007).
However, the degree to which PiB binding to Ab plaques
compared to NFT contributes to in vivo recorded PiB
retention signal, and the basis for region-specific differences
in PiB retention levels in Alzheimer’s disease brains in vivo,
remains to be fully established.
In the present study we addressed these issues by
examining the binding substrates of the highly fluorescent
PiB derivative 6-CN-PiB in Alzheimer’s disease post-
mortem tissues collected from brain regions known to
differentially accumulate neuritic and diffuse Ab plaques
and NFT, and to display differential PiB-PET retention
levels in vivo (Klunk et al., 2004). The physical, pharma-
codynamic and pharmacokinetic properties of 6-CN-PiB
are very similar to PiB (Mathis et al., 2003), but the bright
fluorescence of 6-CN-PiB greatly facilitates histochemical
studies compared to the more weakly fluorescent parent
compound, PiB. These combined histological/immunohis-
tochemical analyses in brain tissue sections were supple-
mented by quantitative biochemical analyses of [
3H]PiB
binding and Ab peptide levels in brain tissue homogenates.
We also examined the brain of an Alzheimer’s disease
subject who underwent PiB-PET imaging 10 months prior
to death, to determine the relationship of ante-mortem
PiB retention levels (determined by PET) to quantitative
measures of 6-CN-PiB and Ab labelled plaque load,
neurofibrillary pathology, [
3H]PiB-binding levels and solu-
ble and insoluble Ab40 and Ab42 peptide levels assessed
post-mortem in the same brain regions of this subject. The
results of these studies provide new insight into the basis
for region-specific patterns of PiB binding in vivo,a n
understanding of which is critical for future evaluation
of PiB-PET imaging during the course of Alzheimer’s
disease, and in the evaluation of effects of anti-amyloid
therapies.
Methods
Clinical and neuropathological information:
autopsy series
Brain tissues were obtained post-mortem from 27 dementia
patients enrolled in the University of Pittsburgh Alzheimer’s
Disease Research Center (ADRC). Clinical diagnosis of
Alzheimer’s disease dementia utilized standard criteria
(McKhann et al., 1984). Mean Mini Mental Examination Score
(MMSE) was 11 8, mean age was 76 11 years and mean
duration of disease was 7 4 years. Neuropathological diagnosis
of ‘definite Alzheimer’s disease’ was made by the established
criteria (Mirra et al., 1991; Consensus, 1998). Fifteen subjects had
no other types of brain pathology besides occasional old infarcts;
11 had concomitant a-synuclein-immunoreactive neocortical Lewy
bodies (Lewy body variant of Alzheimer’s disease), and one subject
had concomitant Parkinson’s disease. Superior frontal and medial
temporal cortices, parahippocampal gyrus, striatum and cerebel-
lum were dissected at autopsy, immersed in cold 4% paraformal-
dehyde for 48h, cryoprotected in sucrose and sectioned at 40
microns on a freezing sliding microtome. Tissue sections were
collected serially in a cryoprotectant solution and stored at  20 C.
Fresh-frozen tissue samples of frontal and occipital cortex grey
matter were obtained from six of these Alzheimer’s disease brains
and were frozen at  80 C until analysis.
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case study
A 64-year-old female with severe Alzheimer’s disease (MMSE=1
at the time of PiB-PET and MR imaging) was followed clinically
in the University of Pittsburgh ADRC for 1 year. Dementia
symptoms were first recorded 8 years prior to her death. Her
apolipoprotein-E genotype was 3/4. The patient’s mother,
maternal aunt and uncle all had onset of Alzheimer’s disease in
their 80s. Her cognitive decline was described by family members
as gradually progressive but more rapid in the 18 months prior to
her death. At autopsy, the brain weighed 1070g and upon gross
examination was unremarkable except for cortical and hippocam-
pal atrophy and minimal atherosclerosis of the circle of Willis.
Multiple brain regions were sampled from the right hemisphere
and flash frozen (unfixed) on dry ice for biochemical analyses; the
left hemisphere was immersed in 10% formalin for histology.
PiB-PETand MRI scans and image analyses:
case study
The subject underwent PiB-PET and MR imaging 10 months prior
to death. Before the PET imaging session, a spoiled gradient
recalled MR scan was obtained for anatomical region-of-interest
(ROI) definition. MRI/PET image co-registration was performed
using automated methods as previously described (Price et al.,
2005). PET scanning also was performed as previously described
(Lopresti et al., 2005); data were acquired using a Siemens/CTI
ECAT HR+ scanner (3-dimensional mode, 63 image planes,
15.2cm axial field of view) following the injection of  555MBq of
high-specific activity (421.4GBq/mmol) PiB. PET emission data
were acquired over 60min (31 frames: 4 15s, 8 30s, 9 60s,
2 180s, 8 300s), corrected for attenuation scatter, and radio-
active decay, and reconstructed using filtered back-projection. The
reconstructed image resolution was  6-mm full width at half
maximum in the transverse and axial planes. PiB retention levels
were determined by the Logan distribution volume ratio (DVR),
with the cerebellum as reference region, and were adjusted for
partial volume effects (see below) (Lopresti et al., 2005). Logan
graphical analyses (Logan et al., 1996) were performed for
35–60min (5 points) intervals using input functions derived
from cerebellar tissue radioactivity to yield the DVR as the out-
come measure (Lammertsma and Hume, 1996). The DVR is a
unitless value related directly to the free binding-site pool (Bmax)
and the ligand dissociation constant (Kd) (Mintun et al., 1984), and
is a measure of region-specific PiB retention (Lopresti et al., 2005).
In vivo^in vitro correlation analyses: case study
From the left (formalin fixed) hemisphere, a 1-cm thick axial
tissue slab was dissected by making a cut along the AC-PC plane
(i.e. along a plane through the anterior and posterior commis-
sures), and a second cut parallel and 1cm dorsal to the AC-PC
plane. This plane of section allowed for sampling from multiple
cortical and subcortical regions known to be differentially affected
with Ab and NFT pathology, and also allowed for precise
sampling of a matching clinical imaging plane. From this 1-cm
thick axial tissue slab, 25 tissue cubes were chosen to sample the
entire cortical ribbon and most of the subcortical nuclei present at
this brain level (see Figs 4 and 5). All tissue cubes were  1 1cm
except cube #25 (hippocampus: 0.5 0.5cm) and cube #19
(occipital pole: polygon) that were adjusted to fit their respective
anatomical boundaries in this axial plane of section. The 25 tissue
cubes were dissected, cryoprotected (as described subsequently)
and sectioned serially at 40mm. Alternate sections were then
divided into two sets. Selected tissue sections from one set were
processed for histochemical staining with 6-CN-PiB, thioflavin-S
(Thio-S) and X-34 compounds, and for immunohistochemistry
(IHC) with anti-Ab and anti-tau antibodies as described below
(Fig. 4). All of the alternate tissue sections from each cube were
combined and homogenized for the [
3H]PiB-binding assay (see
below).
Co-registered MRI and PiB-PET images of the left hemisphere
were oriented along the axial AC-PC plane. Guided by anatomical
landmarks on the ventral surface (i.e. the AC-PC plane) of the
tissue slab, the 25 ROIs were drawn in the AC-PC plane of the
MRI. Except for the slight adjustments necessary due to post-
mortem collapse of the ventricles, all ROIs on the MRI scan
matched the tissue cubes taken from the autopsy tissue slab
(Fig. 5). These ROIs were then copied onto three additional MRI
planes superior to the AC-PC plane for a total of four adjacent
0.24-cm planes, to produce 25 volumes-of-interest (VOIs). The
VOIs were all 1 1 1cm except VOI #25 (caudal portion of the
hippocampus; 0.5 0.5 1cm) and the polygonal VOI #19
(occipital pole). To minimize inclusion of CSF space in the
hippocampal VOI, ROI #25 was moved slightly from plane to
plane. The entire set of 25 VOIs was then transferred from the
MRI scan onto the co-registered PiB-PET scan (Fig. 5).
Histochemically assessed 6-CN-PiB plaque load was calculated
as percent area, and biochemical [
3H]PiB binding and ELISA Ab
levels were calculated as picomoles per gram of tissue wet weight.
Both of these post-mortem measures inherently corrected for
(i.e. exclude) any partial volume effects by focusing only on tissue
and excluding any contribution from CSF spaces. Therefore, the
in vivo PiB-PET DVR values also were adjusted for partial volume
effects by the use of a 2-component MRI-based partial-volume
correction to adjust for the dilutional effect of expanded cerebro-
spinal fluid spaces (Meltzer et al., 1999; Lopresti et al., 2005).
Because the placement of six of the VOI (i.e. 10–13, 15 and 24)
resulted in 570% tissue in the VOI, and this could result in
artefactually high corrected DVR values, only those VOI with
470% tissue (n=19) were included in our analyses.
From the right hemisphere, fresh (unfixed) tissue samples were
dissected from 14 regions: superior (BA9) and middle (BA46)
frontal cortex, frontal pole (BA10), occipital cortex (BA18),
superior (BA41), middle (BA22) and inferior (BA21) temporal
cortex, inferior parietal cortex (BA40), cingulate gyrus (BA31),
caudate nucleus, subiculum/entorhinal cortex, Ammon’s horn,
subcortical white matter and cerebellum. It should be noted that
these frozen tissue samples from right hemisphere did not
correspond exactly to the 25 tissue cubes dissected from the
formalin-fixed (left hemisphere) slab at the AC-PC level, but were
contained within the standard VOI set routinely sampled in our
in vivo PiB-PET studies (Price et al., 2005). Frozen tissue samples
were homogenized (150mg/ml) in a tissue homogenization buffer
[250mM sucrose, 20mM Tris base and protease inhibitors (Sigma
#8340 protease inhibitor cocktail; 10ml per millilitre buffer)] using
a glass vessel and piston-type Teflon pestle. An aliquot of the
150mg/ml homogenate was used for the Ab ELISA; another
aliquot was diluted to 10mg tissue/ml with phosphate-buffered
saline (PBS, pH 7.4) for the [
3H]PiB-binding assay (see below).
For correlation analyses of these post-mortem biochemical assays
and in vivo PiB-PET retention levels, these 14 areas were mapped
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the same day as the PiB-PET study) of the same hemisphere. VOIs
were then transferred to the corresponding PiB-PET image for
calculation of the DVR values (as described earlier), and the values
correlated with the results of Ab ELISA and [
3H]PiB-binding
analyses (as below).
6-CN-PiB, X-34 and Thio-S histofluorescence
Tissue sections were slide mounted and processed for attenuation
of lipofuscin autofluorescence (Guntern et al., 1992). 6-CN-PiB
was used at concentrations of 100nM, 1mM, 10mM and 100mM.
The 10-mM concentration (Table 1) provided the optimal signal to
noise ratio, and was used for the regional and double labelling
analyses in both the autopsy series tissues and in sections from the
25 tissue cubes from the PiB-PET case. Sections were incubated
in 6-CN-PiB for 45 minutes, dipped three times in phosphate
buffer (PB; 0.1M), followed by a 1-min differentiation in a
solution containing 132.9mM NaCl, 8.7mM K2HPO4 and 1.5mM
KH2PO4 (pH 7.4), and coverslipped with Fluoromount (Electron
Microscopy Services, Hatfield, PA). Tissue sections were also
processed for Thio-S or X-34, a fluorescent derivative of Congo
red, as previously described [Table 1; (Ikonomovic et al., 2006)].
Immunohistochemistry
IHC was performed on free-floating tissue sections as previously
described (Ikonomovic et al., 2006). The 4% paraformaldehyde
fixed tissue sections from ADRC Alzheimer’s disease autopsy series
were washed in PB, incubated in 70% formic acid (FA) and
washed in PB. Endogenous peroxidase activity was inhibited by
0.3% H2O2 in 0.1M Tris-buffered saline containing 0.25% Triton
X-100 (TBST) for 45min. Sections were then rinsed in TBST and
incubated in 3% normal serum in TBST for 30min followed by
two 10-min rinses in 1% normal serum in TBST. Sections were
then incubated overnight at 4 C in polyclonal Abx–40 and Abx–42
antisera, or the monoclonal 6E10 (Ab1-16) antibody (Table 1).
Additional primary antibodies included anti-Ab 10D5, pan-tau
and phospho-tau AT8 (Table 1), used as described earlier except
for omission of the FA incubation step. After washing in 1%
normal serum in TBST, sections were incubated for 1h in the
species-appropriate biotinylated IgG (Vector Laboratories,
Burlingame, CA; in 1% normal serum in TBST), except for the
biotinylated 6E10. The sections were washed in TBST and
processed with the avidin-biotin Elite kit (Vector Labs) in TBST
for 1h at room temperature. After washing repeatedly in
imidazole acetate buffer (IAB), they were exposed to a solution
containing 0.05% 30,3-diaminobenzidine tetra-hydrochloride
(DAB)/0.0015% H2O2 for 4min, washed in IAB, mounted on
gelatinized slides, dehydrated in alcohols, cleared in xylene and
coverslipped with Permount (Fischer). The PiB-PET autopsy case
sections were processed identically, with b6E10 and AT8 (Table 1)
IHC performed following a 30-min incubation in 95% FA.
Dual IHC and histochemistry
To detect neuritic plaques, 6-CN-PiB labelled tissue sections were
imaged, photobleached and then counterstained with either X-34
or Thio-S, to determine the extent of 6-CN-PiB labelling of
neuritic plaques (containing X-34 or Thio-S labelled dystrophic
neurites) and neurofibrillary tangles (labelled with either X-34
or Thio-S). The validity of this procedure was confirmed in
an additional set of tissue sections that were either double
immunolabelled with a monoclonal antibody to detect Ab (10D5)
and a polyclonal antiserum to detect tau (Table 1), or single-
labelled with tau, and then counterstained with 6-CN-PiB. Tau
IHC was performed as above, except that alkaline phosphatase-
conjugated secondary antibodies and the Vector Blue substrate
were used, and sections were pre-treated with levamisole (Vector)
to prevent endogenous phosphatase activity. This procedure
distinguished neuritic (10D5-immunoreactive plaques with tau-
immunoreactive dystrophic neurites) and non-neuritic (10D5-
immunoreactive plaques lacking tau- immunoreactive neurites)
plaques. 6-CN-PiB counterstaining of IHC-processed sections
followed removal of the chromogen using the tissue autofluores-
cence quenching procedure (Guntern et al., 1992).
In vitro [
3H]PiB-binding assay
Formalin-fixed tissue samples were homogenized with a Polytron
tissue homogenizer (PT 10/35, Brinkman Instruments Inc.,
Westbury, NY) at room temperature for 30s at setting 6 in PBS
(137mM NaCl, 3mM KCl, 10mM sodium phosphate; pH 7.0) at
a concentration of 10mg brain/ml. Fresh-frozen tissue homo-
genates were diluted from 150mg/ml in tissue homogenization
buffer (see above) to 10mg/ml with PBS and then re-homo-
genized with the PT 10/35 as described earlier. The homogenates
were aliquoted and frozen at  80 C until used (within 2 months)
Table 1 Summary of histofluorescent markers and antisera used for histological and immunohistochemical analyses
Histofluorescent cmpd Affinity Concentration Source (Reference)
6-CN-PiB b-pleated sheet 10mM Dr W.E. Klunk (Mathis et al.,2 0 0 3 )
Thioflavin S b-pleated sheet 0.05% Sigma (Guntern et al.,1 992)
X-34 b-pleated sheet 100mM Dr W.E. Klunk (Ikonomovic et al.,2 0 0 6 )
Antisera (Host) Epitope Dilution
b6E10 (mouse) Ab aa3^10 1:3000 Signet (Kim et al.,1 990)
AT8 (mouse) Ser-202 (P) of tau 1:10,000 Signet (Mercken et al.,1 992)
Ab40 (rabbit) Ala-40; Ab1^40 1:1000 Chemicon (Kamalet al.,2 0 0 1 )
Ab42 (rabbit) Ala-42; Ab1^42 1:1000 Chemicon (Kamalet al.,2 0 0 1 )
K9JA (rabbit) Repeat domain of tau 1:10,000 Dako (Thies et al., 2007)
10D5 (mouse) Ab aa3^6 1:3000 Elan (Hyman et al.,1992)
b=biotinylated.
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acteristics were observed in samples assayed repeatedly over this
time period. Unlabelled PiB was dissolved in DMSO at 400mM (to
yield 51% DMSO in the final assay). This stock solution was
diluted with PBS to achieve the desired concentration in the final
assay. For determination of [
3H]PiB binding in homogenates of
Alzheimer’s disease brains, 1nM [
3H]PiB (American Radiolabeled
Chemicals, St. Louis, MO; specific activity 72.4Ci/mmol) was
incubated with 100mg tissue in 1ml PBS. Non-specific binding
was defined as the number of counts remaining in the presence of
1mM unlabelled PiB. The binding mixtures were filtered through a
Whatman GF/B glass filter using a Brandel M-24R cell harvester
(Gaithersburg, MD) and rapidly washed five times with 3ml PBS.
The filters were counted in Cytoscint-ES after thorough vortexing
and resting overnight. Results were corrected for non-specific,
non-displaceable binding in the presence of 1mM PiB and
expressed as picomoles [
3H]PiB bound per gram of wet tissue
weight in the homogenate. Linearity of [
3H]PiB binding was
confirmed using 1nM [
3H]PiB and 20–500mg/ml of the
Alzheimer’s disease brain homogenate with the highest level of
[
3H]PiB binding. Linearity with respect to [
3H]PiB was confirmed
using 100mg tissue/ml and 1 to 6nM [
3H]PiB. The amount of
[
3H]PiB bound by this method has been shown to correlate highly
with the total number of PiB-binding sites (i.e. the Bmax; r=0.99)
(Klunk et al., 2005) and, importantly, mimics the low nanomolar
concentrations of radioactive PiB achieved in human brain during
a PET study.
For synthetic Ab fibril-binding studies, Ab1–40 or Ab1–42
(Bachem Biosciences, King of Prussia, PA) were aggregated as
previously described (Klunk et al., 2001). Binding studies were
performed with slight modifications of a procedure previously
described in detail (Klunk et al., 2003a). The Kd and Bmax values
for [
3H]PiB binding to Ab fibrils were determined using
increasing concentrations of [
3H]PiB between 0.2 and 1nM and,
to achieve total PiB concentrations from 1 to 1000nM, a constant
1-nM concentration of [
3H]PiB plus additional unlabelled PiB.
The labelled and unlabelled PiB were prepared in 950ml PBS.
Binding was initiated by addition of 50mlo fa4mM suspension of
Ab fibrils in PBS (in triplicate) and the samples were incubated at
22 C for 60min. Filtration was performed as described earlier for
brain homogenates except that the filters were washed only three
times with 3ml PBS before counting.
Ab enzyme linked immunoadsorbant assay
(ELISA)
Ab1–40 and Ab1–42 peptides were quantified in both soluble
(diethylamine, DEA) and insoluble (FA extracted) Ab fractions
following a published protocol (DeKosky et al., 2007). The soluble
fraction was prepared by homogenizing the tissue in 0.4% DEA
in 100mM NaCl, centrifuging at 135000g at 4 C for 1h and
neutralizing the supernatant with 0.5M Tris–Cl. The insoluble
fraction was prepared by homogenizing the pellet in 70% FA for
1min, then centrifuging at 109000g at 4 C for 1h. The
supernatant was then neutralized with 1M Tris, 0.5M sodium
phosphate. Both soluble and insoluble fractions were assayed using
a fluorescent-based ELISA (Biosource; Camarillo, CA) with a
capture antibody specific for the NH2-terminus of Ab (amino
acids 1–16), and detection antibodies specific for Ab peptides
Ab40 and Ab42. Values were determined from standard curves
using synthetic Ab1–40 and Ab1–42 peptides (Biosource) and were
expressed as picomoles per milligram wet brain tissue. ‘Total’ Ab
levels refer to the sum of Ab1–40 and Ab1–42 values.
Plaque load analysis
Plaque load was determined by calculating the percent area
labelled either immunohistochemically (Abx–40,A bx–42, 6E10) or
histofluorescently (6-CN-PiB) in tissue sections. For the ADRC
autopsy series brain tissue, nine randomly chosen areas were
imaged on three sections for each brain region examined from
each case. For correlation of in vivo PiB (PET) DVR levels with
region-matched post-mortem quantitation of 6-CN-PiB histo-
fluorescence and Ab and phosphotau IHC, a 1000 by 750mm field
of the greatest plaque or NFT frequency was imaged in two
sections chosen randomly from each of the 25 tissue cubes; plaque
load was determined from the percent area occupied by
Ab-immunoreactive or 6-CN-PiB positive plaques, while the
AT8 (phosphotau) immunoreactive ‘load’ represented percent
area occupied by all AT8-immunoreactive structures (including
NFTs, neuropil threads and other neuritic elements) in the field.
An independent check of the representative nature of the two
sections chosen randomly for each histological analysis was made
by determining the total Ab plaque load by 6E10 IHC in three
additional sections chosen randomly from each of the 25 tissue
cubes; these data correlated strongly with the original dataset.
Microscope settings were held constant throughout the sampling.
Images were then converted to binary using the public domain
NIH Image program (available at: http://rsb.info.nih.gov/nih-
image/). A predetermined threshold value was held constant
throughout the analysis. Percent area values were obtained by
dividing area labelled by total area sampled.
Statistical analysis
Correlation analyses were performed using Spearman rank order
correlation. Statistical significance was set at 0.05 (two-sided).
Results
Characterization of 6-CN-PiB
histofluorescence in Alzheimer’s disease
brain tissue from autopsy cases
6-CN-PiBbindsprimarilytoAb plaques in Alzheimer’s
disease cortex
At concentrations of 1–10mM, 6-CN-PiB fluorescent signal
was detected almost exclusively in amyloid plaques and
(when present) large, amyloid-laden blood vessels (Fig. 1A).
The morphology of 6-CN-PiB labelled plaques was diverse,
both within and between brain regions examined (see
Table 2 for region-specific plaque terminology). In the
neocortex, entorhinal cortex (ERC) and hippocampus,
6-CN-PiB robustly labelled compact/cored plaques, while
diffuse/amorphous plaques were less prominently labelled
(Fig. 1). No differences in the type of 6-CN-PiB labelled
structures were observed at higher concentrations (e.g.
100mM). At 100nM, the lowest concentration tested, the
overall intensity of 6-CN-PiB fluorescence was considerably
reduced, and diffuse/amorphous plaques in the cortical
and hippocampal regions were difficult to discern while
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detectable. 6-CN-PiB was not detectable in dystrophic
neurites and neuropil threads (see below). Double-labelling
experiments, combining 6-CN-PiB with tau IHC to reveal
the presence or absence of dystrophic neurites in plaques,
demonstrated that 6-CN-PiB labelled plaques both with
(neuritic) and without (non-neuritic) tau-positive dys-
trophic neurites (Fig. 1).
No 6-CN-PiB labelling was detected in brain areas that
were free of Ab plaques as determined by Ab IHC.
There was an apparent one-to-one co-localization between
6-CN-PiB fluorescent plaques and Ab immunoreactive
plaques in cortical regions (Fig. 1), resulting in a direct
correlation between plaque loads determined using these
two markers (r=0.56, P=0.009). 6-CN-PiB labelled both
Ab42- and Ab40-immunoreactive plaques (Supplementary
Fig, 1A–D). Compact/cored Ab40- and Ab42-immunore-
active plaques were most intensely labelled, while diffuse/
amorphous Ab42 deposits were more lightly labelled.
Plaque load analysis (by percent area; see Supplementary
Fig. 1E) demonstrated a direct correlation between cortical
plaque loads determined with 6-CN-PiB and with anti-
bodies to either Ab42 (r=0.82, P=0.0002) or Ab40
(r=0.58, P=0.011).
6-CN-PiB labelling was not detectable in plaque-
containing Alzheimer’s disease tissue sections pre-treated
6-CN-PiB 6-CN-PiB
A B FC HPC
E F
6-CN-PiB Ab   Ab  1-16
6-CN-PiB Tau Tau
C D * *
Fig. 1 Regional variations in 6-CN-PiB fluorescence signal in Alzheimer’s disease brain tissue. In the frontal cortex (FC), 6-CN-PiB
histofluorescence is seen in numerous compact/cored and diffuse plaques, and in an isolated large blood vessel with amyloid angiopathy
(A, arrow). Amorphous diffuse plaques in the hippocampus (HPC; B) are 6-CN-PiB positive, but have lower fluorescence intensity
compared to cored/compact 6-CN-PiB labelled plaques. 6-CN-PiB histofluorescence is prominent in cores of neuritic plaques identified by
the presence of tau-immunoreactive dystrophic neurites (C and D; double labelling of the same Alzheimer’s disease frontal cortex tissue
section with tau IHC; asterisk denotes a tissue landmark, matched plaques are marked by arrows). 6-CN-PiB and Ab immunoreactivity
co-localize in plaques in an Alzheimer’s disease frontal cortex (E,F; tissue section double labelled for 6-CN-PiB histofluorescence and
Ab immuhistochemistry with10D5 antibody). Both markers are seen exclusively in amyloid plaques. Scale bar=175mm( A), 100 mm( B^F).
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et al., 1987), and conversely, treating 6-CN-PiB processed
tissue with formic acid abolished 6-CN-PiB labelling. The
pattern of 6-CN-PiB plaque labelling matched that observed
using two other amyloidal-binding compounds, Thio-S
and X-34 (see Fig. 3); the latter two compounds’ labelling
of plaques was comparable, except that X-34 was more
sensitive in detecting diffuse plaques.
6-CN-PiB is not detectable in cerebellar diffuse plaques
Similar to the pattern of 6-CN-PiB labelling of diffuse
plaques in cortical and hippocampal regions, 6-CN-PiB
labelling was detected in diffuse cloud-like plaques in the
striatum (Fig. 2A); these plaques matched the pattern of
Ab-immunoreactive and X-34 histofluorescent diffuse
plaques in this region (data not shown). In the cerebellum,
however, 6-CN-PiB fluorescence was not detectable in
diffuse plaques, although in adjacent tissue sections there
were abundant diffuse Ab-immunoreactive and X-34-
positive plaques in the cerebellar cortical molecular layer
(Fig. 2B–D). The only types of cerebellar structures
detectable with 6-CN-PiB were large blood vessels (when
present) and small to medium size compact plaques in the
Purkinje cell layer. These structures also showed X-34
fluorescence signal (Fig. 2D inset).
A
D
X-34
6-CN-PiB
STR B
ml
6-CN-PiB
CRBL
CRBL C
Ab1–16
CRBL C
gl
ml
gl
ml
gl
Fig. 2 6-CN-PiB histofluorescence is detectable in cloud-like diffuse plaques in the caudate nucleus of the striatum (STR; A). In the cere-
bellum (CRBL), 6-CN-PiB labelling is not appreciably above background levels (B), although the adjacent tissue sections processed for Ab
IHC (C,10D5 antibody) and X-34 (D) show fleecy diffuse plaques in the molecular layer (ml) of cerebellar cortex (dotted line in B and D
approximates the Purkinje cell layer). In the Purkinje cell layer, some isolated small compact plaques are detectable with both 6-CN-PiB
and X-34 (inserts in B and D; gl, granular layer). Scale bar=150mm( A^D), 75 mm (Inset).
Table 2 6-CN-PiB (10mM) labeling intensity in different
plaque types and amyloid-containing structures in 4%
paraformaldehyde fixed, 40mM thick tissue sections
Plaque type 6-CN-PiB intensity X-34 intensity
Compact/cored (NC, PhG, Crbl)
Neuritic ++++ ++++
Non-neuritic ++++ ++++
Diffuse
Amorphous (NC, PhG) ++ ++
Cloud-like (Str) ++ ++
Fleecy (Crbl) 0 ++
Non-plaque amyloid 6-CN-PiB intensity X-34 intensity
Vascular ++++ ++++
Neurofibrillary tangles iNFT +
a ++++
Neurofibrillary tangles eNFT +++ ++++
Neuropil threads 0 ++++
Dystrophic neurites 0 ++++
0=no 6-CN-PiB fluorescence signal; +=very light fluorescence
barely above backgrounds; ++=light fluorescence;
+++=moderate fluorescence; ++++=intense fluorescence.
NC=neocortex; PhG=parahippocampal gyrus; Str=striatum;
Crbl=cerebellum; iNFT=intracellular NFT; eNFT=extracellular
NFT.
aOnly a small proportion of tangles per section detected in
entorhinal cortex and subiculum.
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neuropil threads and the majority of
neurofibrillary tangles
6-CN-PiB was not detected in neocortical NFT, or in the
vast majority of NFTs in the ERC and subiculum/CA1 that
were detectable with tau IHC and Thio-S or X-34 histology
in the same tissue sections (Fig. 3). In the ERC and
subiculum/CA1, occasional 6-CN-PiB labelled NFT had
a distinct morphology of extracellular ‘tombstone’
tangles (eNFT), enlarged NFT-like structures consisting of
longitudinally oriented bundles of fibrils (Fig. 3C–F). In the
ERC layer II cell islands, there were abundant NFT
intensely labelled by X-34, while 6-CN-PiB labelling of
these NFT was sparse. The same pattern of almost exclusive
labelling of plaques in the ERC was also observed
with BTA-1 (PiB) histochemistry (see Supplementary
Fig. 2). In the hippocampus of one subject with large
numbers of tau-immunoreactive and X-34 labelled intra-
cellular NFT, but no Ab plaques, there was no detectable 6-
CN-PiB labelling (see Supplementary Fig. 3). 6-CN-PiB did
not label neuritic elements such as tau-immunoreactive
C D
EF
Thio-S
B
6-CN-PiB
A
X-34
X-34
6-CN-PiB
6-CN-PiB
Fig. 3 Co-localization of 6-CN-PiB (A,C, E)w i t hT h i o - S( B)a n dX - 3 4( D, F) in plaques, but not in NFT in Alzheimer’s disease temporal
cortex (A, B),a n dh i p p o c a m p u s( C^F). Large cored plaques (double arrows) and small burnt out plaques (arrows) are labelled with both
6-CN-PiB and Thio-S in the temporal cortex, but Thio-S also labels numerous NFT that are not detectable with 6-CN-PiB (A, B).
There is a good co-localization of 6-CN-PiB and X-34 in plaques in the hippocampus (C, D). X-34 also labels an array of neurofibrillary
pathology in the hippocampus (D); only small numbers of these structures are detectable with 6-CN-PiB (C, arrows). E and F represent
boxed areas in C and D, respectively, and illustrate a structure labelled with both 6-CN-PiB and X-34 (small arrow) that resembles an
extracellular NFTwith distinct bundles of longitudinally oriented fibrils that are loosely dispersed in the neuropil. A small diffuse plaque
is also double labelled (empty arrow), while the rest of the X-34 positive NFT in the field are not detectable with 6-CN-PiB. Scale
bar=75mm( A^D), 25 mm( E, F).
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detectable with X-34.
Direct correlation between quantitative
[
3H]PiB binding and Ab peptide (ELISA)
levels in homogenates of Alzheimer’s disease
brain tissue from autopsy cases
In agreement with the 6-CN-PiB labelling of both Ab40
and Ab42 immunoreactive plaques in Alzheimer’s disease
brain tissue as described earlier, [
3H]PiB bound equally
well to synthetic Ab fibrils formed in vitro from either
Ab1–40 or Ab1–42 peptides. The high-affinity Kd for [
3H]PiB
binding was 0.90nM for Ab1–40 and 0.95nM for Ab1–42
(Supplementary Fig. 4A). The Bmax values of the high-
affinity sites were 0.42pmol [
3H]PiB/nmol Ab1–40 and
0.46pmol [
3H]PiB/nmol Ab1–42. This stoichiometry was
similar to that previously reported (Klunk et al., 2005). The
low-affinity components had Kd values of 70–145nM and
thus represent binding that would not be relevant in vivo
where [
11C]PiB concentrations are on the order of 1nM
or less (Klunk et al., 2005). Using 1nM [
3H]PiB, there was
a direct correlation between in vitro [
3H]PiB binding
and total (i.e. combined Ab1–40 and Ab1–42) insoluble Ab in
post-mortem frozen tissue homogenates of frontal and
occipital cortices from six Alzheimer’s disease subjects
(r=0.95, P50.0001, Supplementary Fig. 4B). There was no
significant correlation of [
3H]PiB binding with soluble Ab
peptides.
Direct correlation of in vivo PiB-PETreten-
tion levels with region-matched post-mortem
quantitations of PiB binding, plaque load
and Ab peptide levels
Regional correlations of ante-mortem PiB retention (DVR)
levels and post-mortem analyses of PiB binding and
Alzheimer’s disease pathology in the same individual were
possible because one Alzheimer’s disease subject underwent
in vivo PiB-PET, and a brain autopsy was performed 10
months later. In this case, the final neuropathological
diagnosis by CERAD criteria (Mirra et al., 1991) was
‘definite Alzheimer’s disease’, and the Braak stage (Braak
and Braak, 1991b) was V/VI. No cortical or brainstem Lewy
bodies (assessed by a-synuclein IHC) were present. There
was only minimal cortical gliosis, and no infarcts in
subcortical or cortical structures. Immunohistochemical
analyses demonstrated frequent Ab immunoreactive plaques
and mild amyloid angiopathy. Bielschowsky staining
revealed frequent SP and NFT in all neocortical areas;
this was confirmed with IHC using the anti-phosphotau
antibody clone AT8.
Post-mortem measures of 6-CN-PiB and Ab plaque
loads, AT8-immunoreactive neurofibrillary load and
[
3H]PiB binding were quantified in tissue sections cut
from the 25 tissue cubes in a 1-cm thick tissue slab from
the formalin-fixed left hemisphere. The final analysis
included values from 19 tissue cubes (the MRI VOI of six
of the 25 tissue cubes contained 570% tissue and were
excluded, see Methods section); these values were correlated
with the PiB-PET DVR values from the 19 corresponding
VOIs on the ante-mortem PET scans at the same axial level
of the same hemisphere in this person, after correction for
any partial volume effects (see Methods section). At this
brain level, the highest values for 6-CN-PiB plaque load
were observed in the frontal and temporal cortices, and in
the basal ganglia. The lowest 6-CN-PiB plaque load levels
were in the tail of the hippocampus, internal capsule and
lateral occipital cortex (Fig. 4). This distribution of 6-CN-
PiB plaque load values was similar to the distribution of
PiB DVR values in the same brain regions on the matching
ante-mortem PiB-PET scan (Fig. 5). Figure 4 illustrates the
pattern of 6-CN-PiB labelling and the extent of X-34
labelled amyloid pathology, 6E10 immunoreactive Ab
plaques and AT8 immunoreactive neurofibrillary pathology,
in adjacent tissue sections from three tissue cubes
representative of brain areas with either high-plaque/high-
NFT density (cube #16, frontal cortex), high plaque/low
NFT (cube #1, striatum) or low-plaque/high-NFT density
(cube #25, hippocampus). 6-CN-PiB labelling corresponded
well with Ab plaques revealed by 6E10 IHC, but not with
NFT density as revealed by AT8 IHC (Fig. 4). The overall
X-34 labelling load, which reveals all b-sheet deposits
including Ab plaques and neurofibrillary pathology (NFT,
DN and NT) (Ikonomovic et al., 2006), did not correspond
as well to 6-CN-PiB labelling as did 6E10 IHC for Ab alone.
However, after restricting the analysis to include only X-34
labelled plaques, there was a good correlation between
6-CN-PiB and X-34 plaque load. There was a direct
correlation (r=0.81, P50.0001) of 6-CN-PiB fluorescent
plaque load determined post-mortem with in vivo PiB
retention (Figs 5 and 6A). A similar direct correlation was
found between in vivo PiB DVR values and Ab immunore-
active plaque load (Fig. 6B). In contrast, there was no
correlation between in vivo PiB DVR values and the
neurofibrillary pathology load as revealed by AT8 IHC
(Fig. 6C).
Ab peptide levels could not be quantified by ELISA in
the formalin-fixed tissue homogenate. However, specific,
displaceable [
3H]PiB binding could be detected in this
formalin-fixed tissue. There was a strong significant
correlation (r=0.82, P50.0001) between [
3H]PiB binding
to homogenates of post-mortem formalin-fixed tissue and
PiB DVR values from ante-mortem PET scans (Fig. 6D). In
a separate validation study of six Alzheimer’s disease brains
from our autopsy series, we examined [
3H]PiB binding in
tissues bisected from frontal and occipital cortical samples;
half of each sample was formalin-fixed for three days (to
reproduce the effects of formalin-fixation on the autopsied
brain in the PiB-PET Alzheimer’s disease case study) and
the other half was fresh frozen. Although there was a good
correlation between [
3H]PiB binding to the formalin-fixed
1638 Brain (2008),131,1630^1645 M. D. Ikonomovic et al.and frozen samples (r=0.66; P=0.038), the binding of
[
3H]PiB to the formalin-fixed samples was only 43 24%
of that observed in the corresponding frozen tissue samples.
Therefore, we also measured [
3H]PiB binding in fresh-
frozen tissue samples from 14 brain regions dissected from
the contralateral (frozen) hemisphere of the PiB-PET-
scanned Alzheimer’s disease case. Although the co-localiza-
tion of the VOI used to determine the in vivo DVR value
and the frozen tissue used to measure [
3H]PiB binding
could not be performed as exactly as it could on the
formalin-fixed tissue, there also was a strong correlation of
[
3H]PiB binding with in vivo PiB retention DVR levels in
the frozen tissue (r=0.64, P=0.013, Fig. 6E).
In the same 14 fresh-frozen tissue samples from the right
hemisphere, we next quantified Ab40 and Ab42 peptide
levels for correlations with region-matched in vivo PiB
retention DVR values and in vitro [
3H]PiB binding. There
was a strong correlation of in vivo PiB retention levels with
tissue levels of total (i.e. Ab40+Ab42) insoluble Ab
(r=0.73, P50.0028, Fig. 6F). As observed in frozen frontal
and occipital cortex tissue homogenates from six
Alzheimer’s disease subjects in our autopsy series
(Supplementary Fig. 4B), in the 14 frozen tissue homo-
genates from the PiB-PET scanned Alzheimer’s disease case
there was a strong correlation of in vitro [
3H]PiB binding
with total (i.e. Ab40+Ab42) insoluble Ab (r=0.85,
P=0.0001, Supplementary Fig. 5A). These biochemical
results were supported by a strong correlation between
histological 6-CN-PiB plaque load and 6E10 immunoreac-
tive Ab plaque load in the tissue cubes dissected from
the formalin fixed hemisphere (r=0.86; P50.0001;
Supplementary Fig. 5B).
Discussion
We have defined the histological and biochemical specificity
of PiB binding across different regions of Alzheimer’s
disease brain, and demonstrated a direct correlation
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Fig. 4 6-CN-PiB plaque load (% area) values, quantified in each of the 25 tissue cubes dissected from an axial post-mortem tissue block,
are pseudo-colour-coded on a rainbow scale from black/purple (low% area) to red (high% area). Images of 6-CN-PiB and X-34 histofluor-
escence, and 6E10 and AT8 IHC, were obtained in adjacent tissue sections from tissue cube #16 (frontal cortex), tissue cube #1 (striatum)
and tissue cube #25 (hippocampus), and are each representative of an area with highest concentrations of labelled elements. In all tissue
cubes, 6-CN-PiB exclusively labels plaques, matching the distribution of 6E10 immunoreactive and X-34 labelled plaques, but not AT8
immunoreactive or X-34 labelled NFT, DN and NT . Abbreviations: IC=internal capsule (low background fluorescence in the white matter
tracts); NFT=neurofibrillary tangles; DN=dystrophic neurites; NT=neuropil threads; Hippc=hippocampus; Cx=cortex. Scale
bar=150mm for tissue cube #16 and #1, 75mm for tissue cube #25 and1cm for tissue slab.
PiB-binding substrates in Alzheimer’s disease brain Brain (2008),131, 1630 ^1645 1639between Ab containing amyloid plaques and in vivo PiB
retention measured by PET imaging. The highly fluorescent
PiB analogue, 6-CN-PiB, almost exclusively labelled Ab-
containing structures including compact/cored, diffuse,
neuritic and non-neuritic Ab plaques. 6-CN-PiB also
labelled vascular amyloid, as previously reported (Bacskai
et al., 2007; Lockhart et al., 2007), but fluorescence signal
was not detected in neuropil threads or dystrophic neurites,
and only sporadically in a subset of NFT; these were
primarily of extracellular ‘ghost’ tangle (eNFT) morphol-
ogy. Our study of an Alzheimer’s disease subject who
underwent post-mortem neuropathological examination 10
months after in vivo PiB-PET imaging, demonstrated that
in vivo PiB retention correlated directly with region-
matched post-mortem quantification of 6-CN-PiB and Ab
plaque load, PiB binding and Ab peptide levels, but not
NFT or other neurofibrillary pathology. Although the PiB-
PET study and autopsy were separated by 10 months,
Engler et al. (2006) have shown that PiB-PET DVR values
do not change appreciably over 2 years in patients with
Alzheimer’s disease.
The close co-localization of 6-CN-PiB labelling with
Ab40 and Ab42 immunoreactive plaques, and the in vitro
binding of [
3H]PiB to synthetic fibrils made from either
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Fig. 5 Correlation between ante-mortem PiB-PETretention levels and a post-mortemVOI-matched 6-CN-PiB plaque density map as a
‘virtual PiB scan’of the same subject.The face of the autopsy tissue block is at the level of the anterior and posterior commisures.On the
autopsy tissue (left) each of the 25 blue squares represents the face of a tissue cube that was dissected from this1-cm formalin-fixed slab.
ROIs corresponding to these 25 tissue cubes were drawn on the corresponding four 0.24-cm slices of this same patient’s MRI scan (second
from the left; taken at the time of the PiB scan10 months before death).These same ROIs were then transferred to the co-registered PiB-
PETscan (third from left) for quantification of the in vivo PiB retention. Some tissue distortion post-mortem is evident, due to the collapse
of the ventricles.On the 6-CN-PiB density map (right), the data from the post-mortem regional 6-CN-PiB plaque load analysis (see Fig. 4)
were digitallyblurred to create the‘virtual PiB scan’, shown overlying the contour of the MRI scan for ROI comparison purposes.This post-
mortem 6-CN-PiB plaque density map closely reflects the distribution of PiB retention levels in the PiB-PETscan recorded ante-mortem
in the same person. Abbreviations: InfFG=inferior frontal gyrus; CC:G=corpus callosum: genu; LV:AH=lateral ventricle: anterior horn;
CaNu:H=caudate nucleus: head; IntCap:G=internal capsule: genu; Put=putamen; GP=globus pallidus; STG=superior temporal gyrus;
Ins=insular cortex; IC:PL=internal capsule: posterior limb; Thal=thalamus; Hip=hippocampus; STG=superior temporal gyrus;
LV:OH=lateral ventricle: occipital horn; PHipG=parahippocampal gyrus; MTG=medial temporal gyrus; PVC=primary visual cortex;
CalcSul=calcarine sulcus; OCG=occipital gyrus. Scale bar=1cm.
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Fig. 6 Correlations of the in vivo PiB DVR values from the19 VOIs (six of the 25 VOIs had570% tissue and were not included in the
analysis, see Methods section) on the PETscan with post-mortem quantifications of 6-CN-PiB (A)o rA b (B) plaque load, neurofibrillary
load (C)a n d[
3H]PiB binding (D) in the corresponding19 tissue cubes from the formalin fixed left hemisphere.In vivo PiB-PETretention
(DVR) levels correlate directly with regional post-mortem quantitations of 6-CN-PiB (A)a n d6 E 1 0( B) plaque loads as well asin vitro
PiB binding (D), but not with AT8 neurofibrillary load (C) in formalin-fixed tissue from the left hemisphere. In fresh-frozen tissue from
the right hemisphere of the same Alzheimer’s disease subject, there is a significant correlation of both in vitro PiB binding (E)a n dt o t a l
insoluble Ab (Ab1^40+Ab1^42)p e p t i d el e v e l s( F)w i t hin vivo PiB-PETretention (DVR) levels.
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two forms of Ab, once they have adopted a b-sheet fibrillar
structure. Ab42-containing plaques and Ab42 peptide levels
are much more abundant in Alzheimer’s disease brain
(Iwatsubo et al., 1994; Naslund et al., 2000), and therefore
likely drive the correlation between PiB and total Ab
peptide (Ab42 and Ab40 combined) levels as determined in
our ELISA assays. Thus, the majority of in vivo PiB
retention on PET scans in Alzheimer’s disease reflects
aggregated Ab42 deposits. We did not explore the effect of
the Ab N-terminal heterogeneity on PiB binding, but a
recent paper examining PiB binding to brain tissue from
transgenic mouse models of amyloid deposition suggested
that the form of Ab starting with cyclized glutamate in the
3-position [i.e. pyroglutamate or N3(pE) form] is a major
contributor to PiB binding (Maeda et al., 2007). This is of
interest given the previously reported findings that the
N3(pE) form of Ab comprises 25–50% of total Ab
(Harigaya et al., 2000; Russo et al., 2002).
The requirement that Ab be in fibrillar form for PiB
binding was verified both by the demonstration that formic
acid pre-treatment of tissue sections (which disrupts the
b-sheet fibrillar structure) abolished 6-CN-PiB binding to
plaques and vascular amyloid, and by the direct correlation
of in vitro PiB binding with insoluble (formic acid
extracted) Ab which forms amyloid plaques, but not with
soluble Ab. The intensity of 6-CN-PiB plaque labelling
reflected the density of Ab immunoreactive fibrils in
plaques, from lightly labelled diffuse plaques to intensely
fluorescent compact/cored plaques.
The only region that lacked the close correlation between
6-CN-PiB fluorescence labelling and Ab immunoreactivity
in plaques was the cerebellum. The rare, small compact
plaques in the Purkinje and granular layers, and infrequent
CAA were labelled by 6-CN-PiB. However, fleecy appearing
diffuse plaques in the molecular layer (the vast majority of
Ab immunoreactive and X-34 positive plaques in the
cerebellum) were not detectable with 6-CN-PiB. This is
consistent with the observation that in vivo PiB retention
levels in Alzheimer’s disease brain are consistently lowest in
the cerebellum, and further justifies using the cerebellum as
a reference region when quantifying regional in vivo PiB
retention levels (Lopresti et al., 2005).
The binding of PiB to diffuse plaques in the striatum and
other regions examined, but not in the cerebellum, is likely
due to the unique secondary structure and amino acid
composition of cerebellar diffuse Ab aggregates (Lalowski
et al., 1996). Furthermore, unlike the occasional small
compact plaques that were 6-CN-PiB positive, cerebellar
diffuse plaques contain few amyloid fibrils characteristic of
plaque cores (Verga et al., 1989). The intense 6-CN-PiB
labelling of all compact cored plaques, the weaker labelling
of diffuse cortical, striatal and hippocampal plaques, and
the complete absence of labelling in cerebellar fleecy
amyloid may be due to higher amyloid fibril density in
the compact cored plaques. 6-CN-PiB did not label
dystrophic neurites, indicating that plaque-associated
neuritic elements do not likely contribute to overall PiB
signal, despite the robust labelling of these structures with
other amyloid-binding compounds such as X-34. Because
PiB can detect diffuse plaques in addition to cored and
neuritic plaques, PiB-PET imaging may be useful for
detection of early amyloid deposition. PiB-PET is able to
track Ab deposition across the spectrum of normal aging
to advanced Alzheimer’s disease (Forsberg et al., 2007;
Kemppainen et al., 2007; Rowe et al., 2007), and further
histological studies will need to be performed to assess the
relative contributions of different plaque types across this
spectrum. Compact Ab plaques are likely associated with
increased presence of reactive glial cells. It will be important
to examine correlations of PiB binding with microglial
and astrocytic activation, as well as additional cellular and
molecular alterations, in future studies.
In contrast to the strong correlation between 6-CN-PiB
staining and Ab plaques, 6-CN-PiB did not bind at
detectable levels to significant numbers of NFT, even in
the ERC layer II cell islands where tau-immunoreactive and
X-34 fluorescent NFT were abundant. This is consistent
with the previously reported observation in elderly healthy
control brain of a lack of [
3H]PiB binding to homogenates
of transentorhinal cortex (Klunk et al., 2003b), a brain area
that is the first to show NFT pathology (Braak and Braak,
1991a). These observations differ somewhat from those of
Lockhart et al. (2007), who reported overlap between NFT-
labelling and PiB autoradiography in the ERC. The finding
by Lockhart et al. could be the result of long autoradiog-
raphy exposure time (7 weeks) wherein even the weakest
signal can be amplified, or it could be due to misidentifica-
tion of structures due to the low resolution of film
autoradiography, as well as comparison of different tissue
sections (as opposed to multiple labelling on single tissue
section). In the present study, we did observe weak PiB
labelling of a relatively small subset of NFT, mostly
extracellular NFT detectable in the ERC layer II and
subiculum/CA1, while the majority of intracellular NFT
were not detectable. This pattern was confirmed by
additional histological experiments using another fluores-
cent PiB derivative, BTA-1 (see Supplementary Fig. 2). In
the ERC lamina II, the bulk of NFT were BTA-1 negative,
while small-diameter plaques were BTA-1 positive. This
distinction would not have been detected by the autoradio-
graphic approach used by Lockhart et al. (2007).
Furthermore, in the Lockhart et al. study (Lockhart et al.,
2007), some N-terminus Ab truncated diffuse Ab plaques in
the ERC could have gone undetected by the N-terminus Ab
IHC and thioflavin-S histochemistry. Since select NFT, and
particularly extracellular NFT, contain epitopes recognized
by Ab antibodies (Masters et al., 1985; Grundke-Iqbal et al.,
1989; Hyman et al., 1989; Spillantini et al., 1990; Tabaton
et al., 1991; Perry et al., 1993), we must also consider the
possibility that the NFT labelled by 6-CN-PiB and BTA-1
represent NFT-associated Ab peptides that fibrilized once
1642 Brain (2008),131,1630^1645 M. D. Ikonomovic et al.the NFT became extracellular (Grundke-Iqbal et al., 1989).
Thus, even the occasional labelling of extracellular NFT
observed in this study may be due to the presence of Ab
fibrils, rather than the presence of high-affinity binding
sites on tau-formed amyloid (Lockhart et al., 2007).
Alternatively, extracellular proteolysis of tau in extracellular
NFT may expose the protease-resistant core of PHF, or
change its structure (Mena et al., 1995, 1996) making it
accessible to PiB. Regardless, the binding of PiB to a subset
of NFT produces weak signal relative to that generated by
PiB-bound Ab plaques, and does not likely contribute
significantly to tracer uptake and PiB-PET signal in vivo.
This is supported by the fact that in vivo PiB-PET imaging
studies consistently demonstrated very little signal in mesial
temporal lobe, despite the high NFT load detected both
histologically and immunohistochemically in this region
(see Figs 4 and 5). It should also be noted that the presence
of the cell membrane is not likely the determining factor for
PiB labelling differences between intracellular and extra-
cellular NFT because: (i) the cell membrane is not likely to
be intact in the histological sections; and (ii) PiB has to
cross several membranes which comprise the blood–brain
barrier in order to access either plaques or NFT in vivo.
In this study, the strong labelling of CAA (when present)
by 6-CN-PiB was of similar intensity to compact plaques,
but the frequency of CAA in the typical Alzheimer’s disease
brains we examined was much lower than that of plaques.
Thus in most Alzheimer’s disease subjects, PiB binding to
CAA contributes relatively little to the total in vivo signal,
which appears to be driven primarily by Ab-containing
amyloid plaques. In subjects with amyloid angiopathy
(Johnson et al., 2007) CAA could be a major contribution
to the in vivo PiB signal. However, CAA pathology has
an occipital predilection, resulting in a greater occipital-
to-global PiB ratio compared to Alzheimer’s disease
patients (Johnson et al., 2007). This underscores the need
to interpret the PiB-PET imaging relative to the known
occurrence of neuropathological lesions in the brain areas
under investigation.
Until recently, it was not possible to establish a direct
relationship between PiB retention in vivo and Ab
pathology in the same subject. In a case of pathologically
confirmed dementia with Lewy bodies and severe CAA
(Bacskai et al., 2007), ante-mortem PiB retention levels
correlated with post-mortem biochemical measures of Ab
and PiB binding in three brain regions. PiB binding in this
case was primarily associated with vascular Ab deposits due
to the CAA, while Ab plaques were scarce. This made it
difficult to directly correlate in vivo PiB retention with Ab
plaque deposits in that case, and no correlation was
attempted with histological or immunohistochemical Ab
load. Nevertheless, the results of that study suggested a
correlation between in vivo PiB measures with Ab amyloid
load, and thus are in accord with the present study, which
clearly demonstrates that in vivo PiB retention in a
pathologically typical Alzheimer’s disease patient is related
directly to the amount of insoluble Ab peptides, including
Ab plaques.
Our results underscore the validity of using PiB-PET
scanning not only to detect and follow the progression of
Ab-containing fibrillar amyloid deposits in clinically
defined subject populations, but also to assess effectiveness
of therapies aimed at clearing these potentially toxic
deposits from the brain.
Supplementary material
Supplementary material is available at Brain online.
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